ESSA Pharma Will Fit Into Xtandi, Zytiga Prostate Cancer Treatment Gaps

Emerging Company Profile: ESSA Pharma, a publically traded cancer R&D company, believes it has the answer to drug resistance in patients treated with best-selling cancer therapies Xtandi and Zytiga – as it targets last-line patients with a prostate cancer therapy based on a new mechanism of action.

EmergingCompanyProfiles_1200px
ESSA Pharma wants to fill late-stage prostate cancer treatment gap

ESSA Pharma Inc. is the first company to enter the clinic with a drug program based on a new mechanism of action targeting the N-terminal domain of androgen receptors in metastatic castration-resistant prostate cancer patients.

ESSA Pharma, founded in 2009 in Vancouver, Canada, went public last year on the NASDAQ capital market after relocating some...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Start-Ups & SMEs

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.